|
The FDA has determined that N115 has
sufficient safety toxicology and clinical
data to proceed with the multi-dose,
extended use, clinical trials. Phase II
studies will focus on asthmatics and COPD
patients. On the basis of existing
clinical data, EmphyCorp is confident that
its Investigative New Drug, N115, can and
will be used for maintenance or continuous
treatment of patients over extended
periods of time. The Company believes that
N115 will set the standard in the
pharmaceutical industry for the treatment
of major pulmonary diseases. |
